2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Serologic Tests, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, Research, Translational Research, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3965 Ten-year follow-up of a pilot study of pembrolizumab in treating patients with intermediate or high-risk smoldering multiple myeloma

Charan Thej Reddy Vegivinti, MD, MBBS, Abdur Rehman2, Faezeh Darbaniyan, PhD3, Pranoti Sahasrabhojane4, Donna Marie Weber, MD5, Melody Renee Becnel, MD6, Oren Pasvolsky, MD7, Meera Mohan, MD, MS8, Sarvari V. Yellapragada, MD9, Mahmoud R. Gaballa, MD10, Sheeba Koshy Thomas, M.D.11, Jing Christine Ye, M.D., MSc12, Neeraj Saini, MD13, Behrang Amini, MD, PhD14, Zheng Zhang15, Hans C Lee, MD16, Xingzhi Song17, Xizeng Mao18, Margaret Morgan19, Lei Feng, MS20, Veera Baladandayuthapani21, Andrew Futreal, PhD22, Linghua Wang, MD, PhD23, Christopher R. Flowers Jr, MD, MS24, Krina Patel Jr, MD, MSc25, Sattva S Neelapu Sr, MD26, Elisabet Esteve Manasanch, M.D.27, Robert Orlowski, MD, PhD28
1 The University of Texas MD Anderson Cancer, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, Houston, Texas, United States, The University of Texas MD Anderson Cancer, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 Sarah Cannon Research Institute, Nashville, Tennessee, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 University of Michigan School of Public Health, Ann Arbor, Michigan, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer, Houston, Texas, United States
27 Regeneron pharmaceuticals, New York, New York, United States
28 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, The University of Texas MD Anderson Cancer, Houston, Texas, United States

Background: Smoldering multiple myeloma (SMM) is an asymptomatic precursor to multiple myeloma (MM) with a heterogeneous risk of progression, estimated at approximately 10% per year for the first 5 years. The management of high-risk SMM has evolved considerably, with recent data supporting early intervention using daratumumab (AQUILA trial) and lenalidomide-based regimens. We previously reported results of a pilot study (NCT02603887) evaluating pembrolizumab, an anti-PD-1 monoclonal antibody, in patients with intermediate- and high-risk SMM (I-HR-SMM). In the initial report, 1 of 13 evaluable patients achieved a stringent complete response (sCR) with bone marrow MRD negativity at 10⁻⁴, which was ongoing at 27 months. Here, we report the 10-year follow-up of this cohort, providing the longest available outcome data for PD-1 blockade in SMM.

 Methods: 13 patients with I-HR-SMM by PETHEMA, Mayo, or SWOG criteria were enrolled. Pembrolizumab was administered at 200 mg IV every 21 days for up to 8 cycles, with continuation up to 24 cycles for patients achieving a ≥ minor response. The primary endpoint was overall response rate (ORR) after 8 cycles. Long-term endpoints included time to progression (TTP) to symptomatic MM or change of therapy for HR-SMM, progression-free survival (PFS), overall survival (OS), and durability of response. PFS is defined as progression to MM or change of therapy for SMM. Immune-related adverse events (irAEs) were assessed per CTCAE v5.0.

 Results: 13 patients with I-HR-SMM were enrolled between 08/2016 and 08/2017. The median age was 68 years (range 48-75). The median number of cycles received was 8 (range 2-8), and all 13 were evaluable for safety and efficacy. Median follow-up was 110.2 months (range 12.7–118.2). At the end of treatment, out of 13 patients, one (8%) had sCR, 11 (84%) had stable disease, and one (8%) had PD. The patient who achieved sCR after 3 cycles of pembrolizumab remains in sCR, even at 10 years of follow-up. Among the 11 patients with stable disease in 2017, 4 HR-SMM patients were started on another chemotherapy regimen (Daratumumab or Belantamab, or Isatuximab) for HR-SMM, and none of these patients have progressed to MM. 5 patients (38%) progressed to symptomatic MM, and 4 MM patients were alive at last follow-up; one died due to pulmonary embolism. TTP to MM has not been reached. The median PFS was 35.7 months (range: 4.1–117.4). The estimated 5-year and 10-year PFS rates were 38.5% and 25.6%, respectively. The estimated 10-year OS rate was 92.3% (12/13), and the median OS was not reached.

 The most common irAEs were fatigue (n=8; 75% grade 1, 25% grade 2) and diarrhea (n=6; 83% grade 1, 17% grade 2). Three discontinued for irAEs: grade 3 transaminitis (n=1), grade 2 transaminitis unresolved at 12 weeks (n=1), grade 3 AKI from tubulo-interstitial nephritis (n=1); a fourth discontinued for grade 3 myalgia that was determined not to be an irAE. No grade 4/5 events occurred. The clinical trial was stopped after cycle 2 of Pembrolizumab in the fifth patient as per FDA guidance due to unexpected deaths in MM patients observed in other trials. Notably, the sCR patient had the cohort's highest-risk genomic profile (del(17p), 1q21/CKS1B gain, GEP70 44.9/LB, 50% marrow plasma cells) yet achieved the only sCR, with high baseline PD-1+ T cells, an IFN-γ–enriched signature. Multiplex immunofluorescence of paired marrow biopsies in this patient showed an 11-fold increase in CD3+ T-cell density (10.6 to 116.8 cells/mm²) coincident with a reduction in CD138+ plasma cells (422 to 35 to 212/mm²), providing spatial evidence of an on-treatment immune response.

 Conclusions: Single-agent pembrolizumab was well tolerated in I-HR-SMM, with irAEs limited to grade ≤3 and no grade 4/5 events over 118 months—notably, the FDA halt reflected excess deaths with PD-1/IMiD combinations in active MM, not single-agent toxicity in this setting. At 10 years, PFS was 26% and OS 92%; one patient remains in MRD-negative sCR a decade after three cycles. While PD-1 monotherapy is no longer pursued in SMM given daratumumab (AQUILA) and lenalidomide-based data, this longest-available follow-up of checkpoint blockade in a precursor state shows that a single immune-directed course can yield durable remission in a selected patient. Baseline PD-1 expression and an IFN-γ signature in that responder suggest selection, not strategy, was limiting—supporting biomarker-driven enrollment as immunoprevention advances.

Charan Thej Reddy Vegivinti, MD, MBBS: No relevant conflicts of interest to declare.